Dare Bioscience (DARE) Fundamental Analysis: Revenue, Earnings & Valuation

6.06 / 10

Outperform

Fundamentally, DARE scores 6.1/10, rated Outperform. Strong efficiency metrics—accounts receivable turnover, inventory turnover, and asset utilization—are bullish, yet YoY revenue plunges ‑91% and a negative tax‑to‑profit ratio drag performance. Overall, fundamentals remain favorable despite revenue headwinds.

Analysis Checks(7/10)

Revenue-MV

Value-7.68

Score1/3

Weight20.83%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-91.13

Score0/3

Weight-8.44%

1M Return-2.75%

Inventory turnover ratio

Value47.57

Score3/3

Weight-2.23%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-2.21%

1M Return-0.65%

PB-ROE

Value-0.48

Score2/3

Weight44.06%

1M Return8.98%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-5.02%

1M Return-1.54%

Fixed assets turnover ratio

Value0.00

Score2/3

Weight-3.52%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.49%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-2.45%

1M Return-0.74%

Asset-MV

Value-0.48

Score3/3

Weight61.48%

1M Return13.09%

Is DARE fundamentally strong?

DARE scores 6.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -1300.66% net margin, -1.64 P/E ratio, 7.73 P/B ratio, and -150.00% earnings growth, these metrics solidify its Outperform investment rating.